Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric ulcerative colitis trial of upadacitinib
NL-OMON60206Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in autoimmune colitis (2 arms), sponsored by AbbVie Inc. Primary endpoints: AMS clinical remission at Week 8 and AMS clinical remission at Week 52 among Week 8 responders. Started May 2024; status: completed.
02
Drugs
upadacitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON60206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60206.